Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide on Energy Expenditure in Obesity
NCT06390501Completed
- Sponsor
- Shenzhen Institutes of Advanced Technology
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity comparing Semaglutide with Placebo (2 arms). Primary endpoints: Total Energy Expenditure at 24 weeks, Energy Expenditure at 24 weeks and 2 more. Started Apr 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06390501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390501.